JP2012518398A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012518398A5 JP2012518398A5 JP2011550601A JP2011550601A JP2012518398A5 JP 2012518398 A5 JP2012518398 A5 JP 2012518398A5 JP 2011550601 A JP2011550601 A JP 2011550601A JP 2011550601 A JP2011550601 A JP 2011550601A JP 2012518398 A5 JP2012518398 A5 JP 2012518398A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding
- binding construct
- domain
- construct according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims 28
- 108091007433 antigens Proteins 0.000 claims 28
- 102000036639 antigens Human genes 0.000 claims 28
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 208000001132 Osteoporosis Diseases 0.000 claims 4
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 2
- 208000008035 Back Pain Diseases 0.000 claims 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 2
- 208000000112 Myalgia Diseases 0.000 claims 2
- 208000010191 Osteitis Deformans Diseases 0.000 claims 2
- 206010031243 Osteogenesis imperfecta Diseases 0.000 claims 2
- 208000027868 Paget disease Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 102000014128 RANK Ligand Human genes 0.000 claims 2
- 108010025832 RANK Ligand Proteins 0.000 claims 2
- 102100040247 Tumor necrosis factor Human genes 0.000 claims 2
- 210000003423 ankle Anatomy 0.000 claims 2
- 230000002917 arthritic effect Effects 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000003628 erosive effect Effects 0.000 claims 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 2
- 210000003127 knee Anatomy 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 208000027202 mammary Paget disease Diseases 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 102100024341 10 kDa heat shock protein, mitochondrial Human genes 0.000 claims 1
- 102000003930 C-Type Lectins Human genes 0.000 claims 1
- 108090000342 C-Type Lectins Proteins 0.000 claims 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 108010059013 Chaperonin 10 Proteins 0.000 claims 1
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 claims 1
- 102000016359 Fibronectins Human genes 0.000 claims 1
- 108010067306 Fibronectins Proteins 0.000 claims 1
- 102000019298 Lipocalin Human genes 0.000 claims 1
- 108050006654 Lipocalin Proteins 0.000 claims 1
- 102000000470 PDZ domains Human genes 0.000 claims 1
- 108050008994 PDZ domains Proteins 0.000 claims 1
- 108010079855 Peptide Aptamers Proteins 0.000 claims 1
- 208000018286 Shoulder injury Diseases 0.000 claims 1
- 208000020339 Spinal injury Diseases 0.000 claims 1
- 101000677856 Stenotrophomonas maltophilia (strain K279a) Actin-binding protein Smlt3054 Proteins 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 108090000848 Ubiquitin Proteins 0.000 claims 1
- 102000044159 Ubiquitin Human genes 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000013069 gamma-Crystallins Human genes 0.000 claims 1
- 108010079934 gamma-Crystallins Proteins 0.000 claims 1
- 210000001624 hip Anatomy 0.000 claims 1
- 210000004394 hip joint Anatomy 0.000 claims 1
- 210000001503 joint Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15488009P | 2009-02-24 | 2009-02-24 | |
| US61/154,880 | 2009-02-24 | ||
| PCT/EP2010/052283 WO2010097385A1 (en) | 2009-02-24 | 2010-02-23 | Antigen-binding constructs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012518398A JP2012518398A (ja) | 2012-08-16 |
| JP2012518398A5 true JP2012518398A5 (https=) | 2013-04-11 |
Family
ID=42174088
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011550601A Pending JP2012518398A (ja) | 2009-02-24 | 2010-02-23 | 抗原結合性構築物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20110305692A1 (https=) |
| EP (1) | EP2401298A1 (https=) |
| JP (1) | JP2012518398A (https=) |
| CA (1) | CA2753287A1 (https=) |
| WO (1) | WO2010097385A1 (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2687903C (en) | 2007-05-24 | 2016-09-13 | Ablynx N.V. | Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders |
| WO2010136485A1 (en) * | 2009-05-28 | 2010-12-02 | Glaxo Group Limited | Antigen-binding proteins |
| US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
| DK3622815T3 (da) | 2009-07-08 | 2023-06-26 | Kymab Ltd | Gnavermodeller og terapeutiske molekyler |
| US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
| SMT202600080T1 (it) | 2010-02-08 | 2026-03-09 | Regeneron Pharma | Topo con catena leggera comune |
| US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
| RU2624036C2 (ru) * | 2010-10-27 | 2017-06-30 | Спибер Текнолоджиз Аб | Структуры слитого белка шелка пауков для связывания с органической мишенью |
| EP2683735A1 (en) * | 2011-03-10 | 2014-01-15 | HCO Antibody, Inc. | Bispecific three-chain antibody-like molecules |
| WO2012163887A1 (en) * | 2011-05-27 | 2012-12-06 | Ablynx Nv | Inhibition of bone resorption with rankl binding peptides |
| GB201112429D0 (en) * | 2011-07-19 | 2011-08-31 | Glaxo Group Ltd | Antigen-binding proteins with increased FcRn binding |
| JP5987057B2 (ja) * | 2011-07-27 | 2016-09-06 | グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ | Ｆｃドメインと融合した抗ｖｅｇｆ単一可変ドメイン |
| HUE047278T2 (hu) | 2011-08-05 | 2020-04-28 | Regeneron Pharma | Humanizált univerzális könnyûláncú egerek |
| BR112014006394A2 (pt) | 2011-09-19 | 2017-03-28 | Kymab Ltd | manipulação de diversidade genética de imunoglobulina e terapêuticos multi-anticorpos |
| WO2013045916A1 (en) | 2011-09-26 | 2013-04-04 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
| US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
| US9856308B2 (en) | 2012-05-02 | 2018-01-02 | Spiber Technologies Ab | Spider silk fusion protein structures incorporating immunoglobulin fragments as affinity ligands |
| EP2844360B1 (en) | 2012-05-02 | 2018-12-19 | Spiber Technologies AB | Spider silk fusion protein structures without repetitive fragment for binding to an organic target |
| CA2891510C (en) | 2012-11-16 | 2022-10-18 | Transposagen Biopharmaceuticals, Inc. | Site-specific enzymes and methods of use |
| US9353163B2 (en) | 2013-03-14 | 2016-05-31 | Regeneron Pharmaceuticals, Inc. | Apelin fusion proteins and uses thereof |
| US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
| US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
| US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
| US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
| AU2014330922A1 (en) | 2013-10-01 | 2016-03-03 | Kymab Limited | Animal models and therapeutic molecules |
| WO2015077491A1 (en) | 2013-11-20 | 2015-05-28 | Regeneron Pharmaceuticals, Inc. | Aplnr modulators and uses thereof |
| CA3124228C (en) | 2014-03-21 | 2024-05-14 | Regeneron Pharmaceuticals, Inc. | Non-human animals that make single domain binding proteins |
| US20170107541A1 (en) * | 2014-06-17 | 2017-04-20 | Poseida Therapeutics, Inc. | A method for directing proteins to specific loci in the genome and uses thereof |
| CA2979702A1 (en) | 2015-03-19 | 2016-09-22 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
| US11473082B2 (en) | 2015-06-17 | 2022-10-18 | Poseida Therapeutics, Inc. | Compositions and methods for directing proteins to specific loci in the genome |
| JP2025522957A (ja) * | 2022-07-11 | 2025-07-17 | アムジェン インコーポレイテッド | びらん性変形性手関節症の処置 |
| FR3147292A1 (fr) * | 2023-03-31 | 2024-10-04 | Affyxell Therapeutics Co., Ltd. | Cellules genetiquement modifiees dans lesquelles un acide nucleique codant pour des variantes de la proteine stefine a se liant specifiquement au tnfr2 ou une proteine de fusion comprenant celle-ci a ete introduite, et leurs utilisations |
| CN121013863A (zh) * | 2023-03-31 | 2025-11-25 | 艾菲赛尔治疗株式会社 | Tnfr2结合多肽及使用方法 |
| FR3147278A1 (fr) * | 2023-03-31 | 2024-10-04 | Avacta Life Sciences Limited | Polypeptides de liaison au tnfr2 et procedes d'utilisation |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| CA2140280A1 (en) | 1992-08-17 | 1994-03-03 | Avi J. Ashkenazi | Bispecific immunoadhesins |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| GB9424449D0 (en) | 1994-12-02 | 1995-01-18 | Wellcome Found | Antibodies |
| US5702892A (en) | 1995-05-09 | 1997-12-30 | The United States Of America As Represented By The Department Of Health And Human Services | Phage-display of immunoglobulin heavy chain libraries |
| ES2176484T3 (es) | 1995-08-18 | 2002-12-01 | Morphosys Ag | Bancos de proteinas/(poli)peptidos. |
| ES2230701T3 (es) | 1997-07-07 | 2005-05-01 | Medical Research Council | Procedimiento de seleccion in vitro. |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| GB9809839D0 (en) | 1998-05-09 | 1998-07-08 | Glaxo Group Ltd | Antibody |
| ES2299244T3 (es) | 1998-05-13 | 2008-05-16 | Domantis Limited | Sistema de exposicion de fagos para la seleccion de proteinas correctamente plegadas. |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| GB9900298D0 (en) | 1999-01-07 | 1999-02-24 | Medical Res Council | Optical sorting method |
| AU3040101A (en) | 2000-02-03 | 2001-08-14 | Domantis Limited | Combinatorial protein domains |
| EP1332209B1 (en) | 2000-09-08 | 2009-11-11 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
| EP2295081B1 (en) | 2001-06-26 | 2018-10-31 | Amgen Inc. | Antibodies to OPGL |
| PT1419179E (pt) | 2001-08-10 | 2010-03-16 | Univ Aberdeen | Domínios de ligação de antigenes |
| US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
| AU2003244817B2 (en) | 2002-06-28 | 2010-08-26 | Domantis Limited | Antigen-binding immunoglobulin single variable domains and dual-specific constructs |
| CA2531238C (en) | 2003-07-04 | 2015-02-24 | Affibody Ab | Polypeptides having binding affinity for her2 |
| WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| EP1711196A4 (en) | 2003-12-05 | 2011-09-14 | Bristol Myers Squibb Co | INHIBITORS OF TYPE-2 VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS |
| CA2575402A1 (en) | 2004-08-05 | 2006-02-09 | Genentech, Inc. | Humanized anti-cmet antagonists |
| NZ612578A (en) * | 2005-08-19 | 2014-11-28 | Abbvie Inc | Dual variable domain immunoglobin and uses thereof |
| CA2631184A1 (en) | 2005-11-28 | 2007-05-31 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| MX2008010561A (es) * | 2006-02-15 | 2009-03-02 | Imclone Systems Inc | Anticuerpos funcionales. |
| EP1958957A1 (en) | 2007-02-16 | 2008-08-20 | NascaCell Technologies AG | Polypeptide comprising a knottin protein moiety |
| CA2687903C (en) * | 2007-05-24 | 2016-09-13 | Ablynx N.V. | Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders |
| CA2688433A1 (en) | 2007-06-06 | 2008-12-11 | Domantis Limited | Methods for selecting protease resistant polypeptides |
| GB0724331D0 (en) | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
| CA2726087A1 (en) * | 2008-06-03 | 2009-12-10 | Tariq Ghayur | Dual variable domain immunoglobulins and uses thereof |
-
2010
- 2010-02-23 CA CA2753287A patent/CA2753287A1/en not_active Abandoned
- 2010-02-23 US US13/202,996 patent/US20110305692A1/en not_active Abandoned
- 2010-02-23 EP EP10711861A patent/EP2401298A1/en not_active Withdrawn
- 2010-02-23 JP JP2011550601A patent/JP2012518398A/ja active Pending
- 2010-02-23 WO PCT/EP2010/052283 patent/WO2010097385A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012518398A5 (https=) | ||
| JP2016524592A5 (https=) | ||
| RU2011135422A (ru) | Человеческие анти-il-6 антитела с пролонгированным периодом выведения in vivo и их применение при лечении онкологических, аутоиммунных заболеваний и воспалительных заболеваний | |
| HRP20150799T1 (hr) | Sastavi i postupci za protutijela protiv komplementnog proteina c5 | |
| WO2020076977A3 (en) | Dll3 single domain antibodies and therapeutic compositions thereof | |
| JP2017163973A5 (https=) | ||
| JP2019507589A5 (https=) | ||
| JP2017529067A5 (https=) | ||
| JP2012501670A5 (https=) | ||
| JP2017532952A5 (https=) | ||
| JP2013541335A5 (https=) | ||
| HRP20160131T1 (hr) | Protutijela koja se vežu na izvanstaniäśnu domenu 4 od ljudskog csf1r i njihova uporaba | |
| HRP20180937T1 (hr) | Poboljšavanje transporta terapijskih molekula kroz krvno-moždanu barijeru | |
| MX2012005864A (es) | Proteinas de enlace al antígeno anti-orai 1 y usos de las mismas. | |
| RU2016151265A (ru) | Антитела, направленные на cd127 | |
| JP2018525032A5 (https=) | ||
| HRP20190472T1 (hr) | Klaudin-6 specifični imunoreceptori i t-stanični epitopi | |
| JP2016501839A5 (https=) | ||
| JP2017029157A5 (https=) | ||
| JP2016511254A5 (https=) | ||
| JP2017522903A5 (https=) | ||
| AR080840A1 (es) | Proteinas que se unen al tnf-alfa (factor de necrosis tumoral alfa humano) | |
| RU2016129724A (ru) | Антитела, содержащие с-концевые удлинения полипептида легкой цепи, их конъюгаты и способы применения | |
| RU2016101711A (ru) | Высокостабильный т-клеточный рецептор и способ его получения и применения | |
| JP2020501550A5 (https=) |